326 related articles for article (PubMed ID: 36964457)
1. Clinical benefit of MAO-B and COMT inhibition in Parkinson's disease: practical considerations.
Regensburger M; Ip CW; Kohl Z; Schrader C; Urban PP; Kassubek J; Jost WH
J Neural Transm (Vienna); 2023 Jun; 130(6):847-861. PubMed ID: 36964457
[TBL] [Abstract][Full Text] [Related]
2. [The role of inhibitors of COMT and MAO-B in the therapy of Parkinson's disease].
Woitalla D; Krüger R; Lorenzl S; Müller T; Oelwein G; Storch A; Wolz M; Wüllner U
Fortschr Neurol Psychiatr; 2020 Sep; 88(9):620-633. PubMed ID: 32588409
[TBL] [Abstract][Full Text] [Related]
3. Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial.
Gray R; Patel S; Ives N; Rick C; Woolley R; Muzerengi S; Gray A; Jenkinson C; McIntosh E; Wheatley K; Williams A; Clarke CE;
JAMA Neurol; 2022 Feb; 79(2):131-140. PubMed ID: 34962574
[TBL] [Abstract][Full Text] [Related]
4. The inhibition of catechol O-methyltransferase and monoamine oxidase by tetralone and indanone derivatives substituted with the nitrocatechol moiety.
de Beer AD; Legoabe LJ; Petzer A; Petzer JP
Bioorg Chem; 2021 Sep; 114():105130. PubMed ID: 34225162
[TBL] [Abstract][Full Text] [Related]
5. Nitrocatechol Derivatives of Chalcone as Inhibitors of Monoamine Oxidase and Catechol-O-Methyltransferase.
Engelbrecht I; Petzer JP; Petzer A
Cent Nerv Syst Agents Med Chem; 2018; 18(2):115-127. PubMed ID: 29697034
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
[TBL] [Abstract][Full Text] [Related]
7. Opicapone versus entacapone: Head-to-head retrospective data-based comparison of healthcare resource utilization in people with Parkinson's disease new to catechol-O-methyltransferase (COMT) inhibitor treatment.
Harrison-Jones G; Marston XL; Morgante F; Chaudhuri KR; Castilla-Fernández G; Di Foggia V
Eur J Neurol; 2023 Oct; 30(10):3132-3141. PubMed ID: 37489574
[TBL] [Abstract][Full Text] [Related]
8. A critical appraisal of MAO-B inhibitors in the treatment of Parkinson's disease.
Jost WH
J Neural Transm (Vienna); 2022 Jun; 129(5-6):723-736. PubMed ID: 35107654
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of nitrocatechol chalcone and pyrazoline derivatives as inhibitors of catechol-O-methyltransferase and monoamine oxidase.
Hitge R; Smit S; Petzer A; Petzer JP
Bioorg Med Chem Lett; 2020 Jun; 30(12):127188. PubMed ID: 32299731
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease.
Kaakkola S
Drugs; 2000 Jun; 59(6):1233-50. PubMed ID: 10882160
[TBL] [Abstract][Full Text] [Related]
11. COMT Inhibitors in the Management of Parkinson's Disease.
Fabbri M; Ferreira JJ; Rascol O
CNS Drugs; 2022 Mar; 36(3):261-282. PubMed ID: 35217995
[TBL] [Abstract][Full Text] [Related]
12. Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson's Disease Patients.
Müller T; Schlegel E; Zingler S; Thiede HM
Cells; 2022 Apr; 11(9):. PubMed ID: 35563817
[TBL] [Abstract][Full Text] [Related]
13. Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors.
Chen JJ; Fernandez HH
Drugs Aging; 2007; 24(8):663-80. PubMed ID: 17702535
[TBL] [Abstract][Full Text] [Related]
14. [Relevance of COMT inhibitors in the treatment of motor fluctuations].
Jost WH; Buhmann C; Classen J; Eggert K; Kohl Z; Outeiro T; Tönges L; Woitalla D; Reichmann H
Nervenarzt; 2022 Oct; 93(10):1035-1045. PubMed ID: 35044481
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
16. Are There Benefits in Adding Catechol-O Methyltransferase Inhibitors in the Pharmacotherapy of Parkinson's Disease Patients? A Systematic Review.
Katsaiti I; Nixon J
J Parkinsons Dis; 2018; 8(2):217-231. PubMed ID: 29614697
[TBL] [Abstract][Full Text] [Related]
17. What is the impact of catechol-O-methyltransferase (COMT) on Parkinson's disease treatment?
Salamon A; Zádori D; Szpisjak L; Klivényi P; Vécsei L
Expert Opin Pharmacother; 2022 Jul; 23(10):1123-1128. PubMed ID: 35373688
[No Abstract] [Full Text] [Related]
18. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
Jankovic J; Stacy M
CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled trials.
Yan R; Cai H; Cui Y; Su D; Cai G; Lin F; Feng T
Eur J Neurol; 2023 Apr; 30(4):1118-1134. PubMed ID: 36437702
[TBL] [Abstract][Full Text] [Related]
20. Identification and optimization of nitrophenolic analogues as dopamine metabolic enzyme inhibitors for the treatment of Parkinson's disease.
Zou M; Wu Y; Lan Y; Xie H; Sun H; Liu W; Feng F; Jiang X
Bioorg Chem; 2024 Jul; 148():107488. PubMed ID: 38797066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]